EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status

Franziska S Ulrich iD, Nicola Napoli iD, Morten Frost Nielsen iD, Andrea M Burden iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70535 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Franziska S Ulrich und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Glucagon-Like Peptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Foundation for Medical-Biological Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Real‐world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP ‐1 receptor agonist ( GLP ‐ 1RA ) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, obesity status, cardiovascular disease ( CVD ) history, and sex assigned at birth. Materials and methods Adults with type 2 diabetes initiating GLP‐1RAs between 1 March 2018 and 30 June 2023, with follow‐up ≥1‐year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database. The absolute 1‐year risk of discontinuation was estimated using the Aalen‐Johansen estimator, while multivariable cause‐specific Cox models assessed associations with patient characteristics. Dosing trajectories were characterised across individual prescriptions during the first therapy year.

Results

Among 8200 GLP‐1RA initiators (46.5% dulaglutide, 38.7% semaglutide), the 1‐year discontinuation risk was 41.1% (95% CI 40.1–42.2), higher among those without obesity (BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsObesityGlucagon-Like PeptidesCardiovascular DiseasesHypoglycemic AgentsRecombinant Fusion ProteinsHumansFemaleMaleUnited KingdomSemaglutideMiddle AgedAgedImmunoglobulin Fc FragmentsCohort StudiesAdultDose-Response Relationship, Drug

Stichwörter der Autor:innen

GLP‐1 receptor agonistType 2 diabetesUnited Kingdomcardiovascular diseasedose titrationdrug utilisationglucose‐lowering therapyobesityprimary carereal‐world evidencetreatment discontinuation

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideGlucagon-Like PeptidesHypoglycemic AgentsdulaglutideImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
  • Unit of Endocrinology and Diabetes, Campus, Bio-Medico University of Rome, Rome, Italy.
  • Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus, Bio-Medico University of Rome, Rome, Italy.
  • Division of Bone and Mineral Diseases, Washington University, St Louis, Missouri, USA.
  • Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark.

ORCID-Profile: Franziska S Ulrich, Nicola Napoli, Morten Frost Nielsen, Andrea M Burden

Förderung

  • Novartis Foundation for Medical-Biological Research

Zitieren

APA

Ulrich, F. S., Napoli, N., Nielsen, M. F., & Burden, A. M. (2026). Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70535

Vancouver

Ulrich FS, Napoli N, Nielsen MF, Burden AM. Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70535

BibTeX
@article{Ulrich2026,
  author = {Ulrich, Franziska S and Napoli, Nicola and Nielsen, Morten Frost and Burden, Andrea M},
  title = {Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70535}
}
Kostenlos starten →